Advertisement

Breast Disease pp 281-292 | Cite as

Surgical Treatment in Operable Breast Cancer After Neoadjuvant Systemic Therapy

  • Atilla SoranEmail author
  • Ebru Menekse
  • Kandace P. McGuire
Chapter

Abstract

The primary goal of neoadjuvant chemotherapy (NCT) in operable breast cancer is tumor downsizing to facilitate breast-conserving surgery (BCS), and it may give a chance for less aggressive lymph node surgery. The use of NCT in early-stage breast cancer in carefully selected patients is increasing. Despite a shift in the treated patient population to patients with earlier-stage tumors, the principles of surgery after NCT remain the same. Monitoring response to therapy is important for surgical planning and prognostic information. Preoperative marking of the tumor is essential for guiding BCS after NCT and should be performed in all patients. Early literature supported the use of pre-NCT sentinel lymph node biopsy (SLNB), but current literature suggests increased accuracy and decreased use of axillary dissection in patients who undergo SLNB after NCT regardless of clinical lymph node status prior to NCT. A multidisciplinary approach to breast cancer care is essential during NCT for improved outcomes and decreased morbidity.

Keywords

Breast cancer Chemotherapy Neoadjuvant treatment Surgery Surgical procedure 

References

  1. 1.
    Kummel S, Holtschmidt J, Loibl S. Surgical treatment of primary breast cancer in the neoadjuvant setting. Br J Surg. 2014;101(8):912–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. Chicago: Springer; 2010. p. 345–76.Google Scholar
  3. 3.
    Breast Cancer. NCCN clinical practice guidelines in oncology 2018. 3.2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 25 Oct 2018.
  4. 4.
    Mieog JS, van de Velde CJ. Neoadjuvant chemotherapy for early breast cancer. Expert Opin Pharmacother. 2009;10(9):1423–34.PubMedCrossRefGoogle Scholar
  5. 5.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomized trials. Lancet Oncol. 2018;19(1):27–39.CrossRefGoogle Scholar
  6. 6.
    Redden MH, Fuhrman GM. Neoadjuvant chemotherapy in the treatment of breast cancer. Surg Clin North Am. 2013;93(2):493–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014;23(3):505–23.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–98.PubMedCrossRefGoogle Scholar
  11. 11.
    Rapoport BL, Demetriou GS, Moodley SD, Benn CA. When and how do I use neoadjuvant chemotherapy for breast cancer? Curr Treat Options in Oncol. 2014;15(1):86–98.CrossRefGoogle Scholar
  12. 12.
    Warren RM, Bobrow LG, Earl HM, Britton PD, Gopalan D, Purushotham AD, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer. 2004;90(7):1349–60.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, Samulski TV, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol. 2003;181(5):1275–82.CrossRefGoogle Scholar
  14. 14.
    Marinovich ML, Sardanelli F, Ciatto S, Mamounas E, Brennan M, Macaskill P, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast. 2012;21(5):669–77.PubMedCrossRefGoogle Scholar
  15. 15.
    Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 2018;10:4333–47.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 2011;18(11):3149–54.PubMedCrossRefGoogle Scholar
  17. 17.
    De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;119(10):1776–83.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling J, et al. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. PLoS One. 2017;12(5):e0176782.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.CrossRefGoogle Scholar
  20. 20.
    Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30(30):96–102.CrossRefGoogle Scholar
  21. 21.
    Teshome M, Kuerer HM. Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. Eur J Surg Oncol. 2017;43(5):865–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002;86(7):1041–6.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94(10):1189–200.PubMedCrossRefGoogle Scholar
  24. 24.
    Ellis MJ. Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer. Breast. 2017;34(Suppl 1):S104–7.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla C, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 1995;222(5):612–8.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Kuerer HM, Vrancken Peeters MTFD, Rea DW, Basik M, De Los Santos J, Heil J. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials. Ann Surg Oncol. 2017;24(10):2855–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008;26(5):791–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Loibl S, von Minckwitz G, Raab G, Blohmer JU, Dan Costa S, Gerber B, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13(11):1434–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Spronk PER, Volders JH, van den Tol P, Smorenburg CH, Vrancken Peeters MTFD. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit. Eur J Surg Oncol. 2019;45(2):110–117.PubMedCrossRefGoogle Scholar
  30. 30.
    Hoffman KE, Mittendorf EA, Buchholz TA. Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol. 2012;13(6):e270Ð6.CrossRefGoogle Scholar
  31. 31.
    Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88(1):65–72.PubMedCrossRefGoogle Scholar
  32. 32.
    Kronowitz SJ, Robb GL. Radiation therapy and breast reconstruction: a critical review of the literature. Plast Reconstr Surg. 2009;124(2):395–408.PubMedCrossRefGoogle Scholar
  33. 33.
    Berbers J, van Baardwijk A, Houben R, et al. ‘Reconstruction: before or after postmastectomy radiotherapy?’ A systematic review of the literature. Eur J Cancer. 2014;50(16):2752–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Agresti R, Sandri M, Gennaro M, Bianchi G, Maugeri I, Rampa M, et al. Evaluation of local oncologic safety in nipple-areola complex-sparing mastectomy after primary chemotherapy: a propensity score-matched study. Clin Breast Cancer. 2017;17(3):219–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guide-line update. J Clin Oncol. 2014;32(13):1365–83.PubMedCrossRefGoogle Scholar
  36. 36.
    Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(5):561–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Posther KE, McCall LM, Blumencranz PW, Burak WE Jr, Beitsch PD, Hansen NM, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005;242(4):593–9.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Mamounas EP. Timing of determining axillary lymph node status when neoadjuvant chemotherapy is used. Curr Oncol Rep. 2014;16(2):364.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Shimazu K, Noguchi S. Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer. Surg Today. 2011;41(3):311–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Iwase H, Yamamoto Y, Kawasoe T, Ibusuki M. Advantage of sentinel lymph node biopsy before neoadjuvant chemotherapy in breast cancer treatment. Surg Today. 2009;39(5):374–80.PubMedCrossRefGoogle Scholar
  43. 43.
    Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, et al. Implementation of the American College of Surgeons Oncology Group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014;21(8):2468–73.PubMedCrossRefGoogle Scholar
  44. 44.
    Pecha V, Kolarik D, Kozevnikova R, Hovorkova K, Hrabetova P, Halaska M, et al. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Cancer. 2011;117(20):4606–16.PubMedCrossRefGoogle Scholar
  45. 45.
    Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27(5):726–32.PubMedCrossRefGoogle Scholar
  46. 46.
    Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2018;173(2):343–52.PubMedCrossRefGoogle Scholar
  47. 47.
    Murphy BL, L Hoskin T, Heins CDN, Habermann EB, Boughey JC. Preoperative prediction of node-negative disease after neoadjuvant chemotherapy in patients presenting with node-negative or node-positive breast cancer. Ann Surg Oncol. 2017;24(9):2518–25.PubMedCrossRefGoogle Scholar
  48. 48.
    Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–8.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64.PubMedCrossRefGoogle Scholar
  51. 51.
    Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy – results from the multi-center SENTINA trial. Breast. 2017;31:202–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Boughey JC, Ballman KV, Hunt KK, McCall LM, Mittendorf EA, Ahrendt GM, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33(30):3386–93.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Schipper RJ, Moossdorff M, Beets-Tan RGH, Smidt ML, Lobbes MBI. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review. Eur J Radiol. 2015;84(1):41–7.PubMedCrossRefGoogle Scholar
  54. 54.
    You S, Kang DK, Jung YS, An YS, Jeon GS, Kim TH. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and 18F-FDG PET/CT. Br J Radiol. 2015;88(1052):20150143.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Liedtke C, Kolberg HC, Kerschke L, Görlich D, Bauerfeind I, Fehm T, et al. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). Clin Exp Metastasis. 2018;35(8):777–83.PubMedCrossRefGoogle Scholar
  56. 56.
    Mamounas E. NSABP B-51/RTOG 1304: Randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC. Paper presented at: ASCO annual meeting; Chicago; 2014.CrossRefGoogle Scholar
  57. 57.
    Smith BD. Using chemotherapy response to personalize choices regarding locoregional therapy: a new era in breast cancer treatment? J Clin Oncol. 2012;30(32):3913–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat. 2012;136(2):487–93.PubMedCrossRefGoogle Scholar
  59. 59.
    Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, et al. Phosphorylated ER alpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 2009;27(2):227–34.PubMedCrossRefGoogle Scholar
  60. 60.
    Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–54.PubMedCrossRefGoogle Scholar
  61. 61.
    Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–32.PubMedCrossRefGoogle Scholar
  62. 62.
    Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker out-comes and predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Gianni L, Pienkowski T, Im Y-H et al. Five-year analysis of the phase II Neosphere trial evaluating for cycles of neoadjuvant docetaxel (D) and/or transtuzumab (T) and/or pertuzumab (P). ASCO meetings abstracts. 2015; 33:505. Available at: meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/505.CrossRefGoogle Scholar
  64. 64.
    Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.PubMedCrossRefGoogle Scholar
  65. 65.
    Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016;23(3):749–56.PubMedCrossRefGoogle Scholar
  67. 67.
    Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188–94.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, et al. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006;66(2):352–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C, et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: an international collaboration and individual patient meta-analysis. Cancer. 2018;124(14):2923–30.PubMedCrossRefGoogle Scholar
  70. 70.
    Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM. Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg. 1991;213(2):126–9.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Unalp HR, Onal MA. Analysis of risk factors affecting the development of seromas following breast cancer surgeries: seromas following breast cancer surgeries. Breast J. 2007;13(6):588–92.PubMedCrossRefGoogle Scholar
  72. 72.
    Narui K, Ishikawa T, Satake T, Adachi S, Yamada A, Shimada K, et al. Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy. Eur J Surg Oncol. 2014;41(1):94–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Donker M, Hage JJ, Woerdeman LA, Rutgers EJ, Sonke GS, Vrancken Peeters MJ. Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer. Eur J Surg Oncol. 2012;38(1):25–30.PubMedCrossRefGoogle Scholar
  74. 74.
    Wilke LG, Ballman KV, McCall LM, Giuliano AE, Whitworth PW, Blumencranz PW, et al. Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010. Ann Surg Oncol. 2010;17(8):1989–94.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Jung SY, Shin KH, Kim M, Chung SH, Lee S, Kang HS, et al. Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients. Breast Cancer Res Treat. 2014;148(1):91–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Atilla Soran
    • 1
    Email author
  • Ebru Menekse
    • 1
  • Kandace P. McGuire
    • 2
    • 3
  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of Pittsburgh School of Medicine, Magee-Women’s Hospital of UPMCPittsburghUSA
  2. 2.Division of Surgical Oncology, Department of SurgeryVirginia Commonwealth UniversityRichmondUSA
  3. 3.Section of Breast SurgeryMassey Cancer Center at Virginia Commonwealth UniversityRichmondUnited States

Personalised recommendations